Personalized Magnetic Stimulation Shows Promise in PTSD Trial

Personalized magnetic stimulation could give people with post-traumatic stress disorder another treatment option, and early trial results reported by Wave Neuroscience are striking: a 52% reduction in symptoms and remission for 68% of participants. The findings are not yet publicly available in full, so they offer an encouraging signal rather than a settled comparison with established care.

The system, developed by California-based Wave Neuroscience with researchers at the Texas A&M Health Institute of Biosciences and Technology, uses brain activity measurements to tailor transcranial magnetic stimulation (TMS). Its FDA clearance marks a new treatment path for PTSD built around individualized stimulation. Whether that path proves useful at scale will depend on the full evidence and on patients being able to access the therapy.

What the early results show

Wave’s reported outcomes stand out against results from earlier medication research. A 2020 review found that PTSD medication studies reported symptom-assessment improvements of 6.8 to 10.1 points, with remission rates reaching no more than 10.9%. Wave chief medical officer Erik Won, DO, described the trial’s 52% symptom reduction as more than four times the efficacy reported in that review, and pointed to the 68% remission figure as especially meaningful.

Those figures come from different studies, however, and shouldn’t be read as a direct head-to-head comparison. The complete findings from Wave’s trial are still being prepared for release. Until they are available, the public has limited information for assessing how participants were selected, how outcomes were measured, or how the results compare with other treatments under similar conditions.

The trial involved five treatment sessions per week over five to six weeks. Researchers said improvements appeared to persist after treatment ended, which raises the possibility of lasting benefits. The source material does not provide a longer follow-up period or detailed results by patient group, leaving important questions for the full report to address.

How MeRT personalizes TMS

Wave calls its approach Magnetic e-Resonance Therapy, or MeRT. It starts with an electroencephalogram (EEG), which records electrical activity in the brain. Those measurements feed an AI-assisted algorithm that helps set an individualized TMS protocol. During treatment, a coil held against the scalp delivers magnetic pulses intended to stimulate brain activity.

TMS already has FDA clearance for treatment-resistant depression. MeRT applies the underlying technique to PTSD with protocols guided by each patient’s EEG data. The distinction is that the stimulation plan is adjusted to a person’s measured brain activity rather than relying on a standardized regimen.

That approach reflects a broader precision-medicine idea: people can respond differently to the same intervention, so treatment choices may improve when they account for individual biology. Texas A&M physician-scientist Kenneth S. Ramos, who helped guide the research, said even small biological differences can matter in medical care. He compared conventional TMS to putting a tarp over a leaking roof, while describing MeRT as an attempt to identify and replace the damaged shingles. The analogy captures the aim of personalization, though the clinical evidence will determine how well the method delivers on it.

A different option for some patients

PTSD care has largely relied on psychotherapy and medications, including selective serotonin reuptake inhibitors such as sertraline and fluoxetine. These treatments can help, but some people continue to experience symptoms. Psychotherapy also demands active participation, and Texas A&M psychiatrist Israel Liberzon said some patients leave treatment because it can provoke anxiety.

Liberzon, the trial’s lead psychiatrist and PTSD specialist, said the system would add a nonmedication option specifically cleared for PTSD. He noted that the FDA has approved two medications for the condition, both SSRIs, while psychotherapy is also widely used. MeRT could therefore broaden the choices available to patients who struggle with medication side effects or find psychotherapy difficult to complete. That possibility does not establish that it will suit every patient or replace existing care.

The need for additional options is significant. The source reports that about 7% of veterans receive a PTSD diagnosis each year, and estimates that 6% of Americans will experience PTSD during their lifetime, with higher rates among women and veterans. PTSD can follow experiences including combat, serious accidents, natural disasters, and violence. It has been formally recognized as a diagnosis since 1980.

Clearance and access remain key tests

MeRT received an FDA Breakthrough Device designation in 2024, a milestone in the development process. Texas A&M clinical trials executive director Rick Silva said the designation can support communication with regulators and reduce administrative delays while retaining scientific and medical requirements. Silva said the project moved from its pandemic-era beginnings through the relevant process in just over two years, compared with around 10 years that medical device development and clinical evaluation can often take.

Clearance is only one part of turning a new therapy into a practical treatment. Wave and Texas A&M are working with other stakeholders to expand availability and make the therapy more affordable through insurance coverage. The source provides no details on current coverage, pricing, or how quickly patients might gain access.

Wave CEO Fred Walke and chief scientific officer Leslie S. Prichep have described the system as part of a broader effort to use objective measurements of brain function to guide mental health care. That ambition reaches beyond PTSD: Won said the company believes the technology could eventually be adapted for conditions such as depression and anxiety. Those possibilities remain future prospects, while PTSD is the condition addressed by the current clearance.

For now, MeRT’s reported trial outcomes make it a treatment to watch, not a conclusion about what works best. The full study results, evidence on how long benefits last, and practical access will show whether personalized stimulation can become a dependable part of PTSD care.